Welcome to LookChem.com Sign In|Join Free
  • or
O-Isobutylhydroxylamine Hydrochloride is an organic compound that serves as a reagent in the synthesis of various chemical compounds. It is characterized by its ability to act as a precursor in the preparation of bis-hydroxy-benzophenone oxime ether derivatives, which have potential applications in pharmaceutical and medical fields.

6084-58-8

Post Buying Request

6084-58-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6084-58-8 Usage

Uses

Used in Pharmaceutical Industry:
O-Isobutylhydroxylamine Hydrochloride is used as a reagent for the preparation of bis-hydroxy-benzophenone oxime ether derivatives. These derivatives function as estrogen receptor (ER) agonists and exhibit complementary anti-cancer activities, making them valuable in the development of novel therapeutic agents for the treatment of cancer.
In the context of cancer treatment, bis-hydroxy-benzophenone oxime ether derivatives have the potential to target estrogen receptor-positive tumors, offering a new avenue for cancer therapy. The use of O-Isobutylhydroxylamine Hydrochloride in the synthesis of these compounds highlights its importance in advancing pharmaceutical research and drug development.

Check Digit Verification of cas no

The CAS Registry Mumber 6084-58-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,0,8 and 4 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 6084-58:
(6*6)+(5*0)+(4*8)+(3*4)+(2*5)+(1*8)=98
98 % 10 = 8
So 6084-58-8 is a valid CAS Registry Number.
InChI:InChI=1/C4H11NO.ClH/c1-4(2)3-6-5;/h4H,3,5H2,1-2H3;1H

6084-58-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Isobutyloxyamine Hydrochloride

1.2 Other means of identification

Product number -
Other names O-(2-methylpropyl)hydroxylamine,hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6084-58-8 SDS

6084-58-8Synthetic route

O-1-(2-methyl)propyl-N-hydroxyphthalimide
52026-51-4

O-1-(2-methyl)propyl-N-hydroxyphthalimide

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
Stage #1: O-1-(2-methyl)propyl-N-hydroxyphthalimide With methylhydrazine In dichloromethane at 0 - 20℃; for 2h;
Stage #2: With hydrogenchloride In 1,4-dioxane at 0℃;
99%
With hydrazine In ethanol; water for 2h; hydrazinolysis; Heating;31.9%
With methylhydrazine In dichloromethane
Stage #1: O-1-(2-methyl)propyl-N-hydroxyphthalimide With hydrazine hydrate In dichloromethane Inert atmosphere;
Stage #2: With hydrogenchloride In 1,4-dioxane Inert atmosphere;
C6H13NO2

C6H13NO2

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In ethanol; water at 65℃;61.8%
With hydrogenchloride In ethanol; water at 65℃;61.8%
C13H15NO2

C13H15NO2

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
Stage #1: C13H15NO2 With hydrazine hydrate In tetrahydrofuran at 20℃; for 12h;
Stage #2: With hydrogenchloride In 1,4-dioxane at 20℃; for 0.0833333h;
53%
O-isobutylhydroxylamine
5618-62-2

O-isobutylhydroxylamine

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In ethanol at 0 - 5℃; for 72h;
4,4'-Dihydroxybenzophenone
611-99-4

4,4'-Dihydroxybenzophenone

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

bis(4-hydroxyphenyl)methanone O-isobutyl oxime

bis(4-hydroxyphenyl)methanone O-isobutyl oxime

Conditions
ConditionsYield
In ethanol at 20℃; Inert atmosphere;99%
2,7-bis(N'-ethoxycarbonylthiourea)-9H-fluorene
853579-43-8

2,7-bis(N'-ethoxycarbonylthiourea)-9H-fluorene

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

2,7-bis(N'-ethoxycarbonyl-N''-isobutoxy)guanidino-9H-fluorene
853579-28-9

2,7-bis(N'-ethoxycarbonyl-N''-isobutoxy)guanidino-9H-fluorene

Conditions
ConditionsYield
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In 1,4-dioxane; dichloromethane at 20℃;93%
methyl 2-(4-hydroxybenzyl)-3-oxobutanoate
157284-85-0

methyl 2-(4-hydroxybenzyl)-3-oxobutanoate

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

3-(2-methyl-propyl)oxyimino-2-(4-hydroxy-benzyl)-butyric acid methyl ester
851181-35-6

3-(2-methyl-propyl)oxyimino-2-(4-hydroxy-benzyl)-butyric acid methyl ester

Conditions
ConditionsYield
With sodium acetate In methanol90%
With triethylamine In ethanol at 45℃; for 24h;80%
methyl 3-acetyl-5-(dipropylcarbamoyl)-benzoate
924650-01-1

methyl 3-acetyl-5-(dipropylcarbamoyl)-benzoate

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C21H32N2O4
1163142-89-9

C21H32N2O4

Conditions
ConditionsYield
In ethanol at 80℃;85%
O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

benzyl chloroformate
501-53-1

benzyl chloroformate

benzyl N-(isobutyloxy)carbamate
1174758-23-6

benzyl N-(isobutyloxy)carbamate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; Inert atmosphere;84%
C31H44O7
1446092-98-3

C31H44O7

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

((2R,3S)-3-acetoxy-6-((3S,10R,13S,17S)-17-((E)-1-(isobutoxyimino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate

((2R,3S)-3-acetoxy-6-((3S,10R,13S,17S)-17-((E)-1-(isobutoxyimino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate

Conditions
ConditionsYield
With pyridine for 3h; Reflux;84%
C31H44O7
1446092-98-3

C31H44O7

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C35H53NO7

C35H53NO7

Conditions
ConditionsYield
With pyridine at 80℃; for 4h; Inert atmosphere;84%
C32H48O9

C32H48O9

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C36H57NO9

C36H57NO9

Conditions
ConditionsYield
With pyridine at 20℃;80%
4-chloro-2-pyridine carboxylic acid chloride hydrochloride

4-chloro-2-pyridine carboxylic acid chloride hydrochloride

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

4-chloro-N-isobutoxypicolinamide
953771-92-1

4-chloro-N-isobutoxypicolinamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; for 0.5h;67%
[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-acetic acid

[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-acetic acid

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

2-[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-N-isobutoxy-acetamide

2-[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-N-isobutoxy-acetamide

Conditions
ConditionsYield
Stage #1: [(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-acetic acid With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran; dichloromethane at 0℃; for 0.0833333h;
Stage #2: O-isobutylhydroxylamine hydrochloride With triethylamine In tetrahydrofuran; dichloromethane at 0℃; for 16h;
67%
O-1-(2-methyl)propyl-N-hydroxyphthalimide
52026-51-4

O-1-(2-methyl)propyl-N-hydroxyphthalimide

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
Stage #1: O-1-(2-methyl)propyl-N-hydroxyphthalimide With methylhydrazine In dichloromethane at 0 - 20℃; for 2h;
Stage #2: With hydrogenchloride In 1,4-dioxane at 0℃;
99%
With hydrazine In ethanol; water for 2h; hydrazinolysis; Heating;31.9%
With methylhydrazine In dichloromethane
Stage #1: O-1-(2-methyl)propyl-N-hydroxyphthalimide With hydrazine hydrate In dichloromethane Inert atmosphere;
Stage #2: With hydrogenchloride In 1,4-dioxane Inert atmosphere;
C6H13NO2

C6H13NO2

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In ethanol; water at 65℃;61.8%
With hydrogenchloride In ethanol; water at 65℃;61.8%
C13H15NO2

C13H15NO2

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
Stage #1: C13H15NO2 With hydrazine hydrate In tetrahydrofuran at 20℃; for 12h;
Stage #2: With hydrogenchloride In 1,4-dioxane at 20℃; for 0.0833333h;
53%
O-isobutylhydroxylamine
5618-62-2

O-isobutylhydroxylamine

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In ethanol at 0 - 5℃; for 72h;
4,4'-Dihydroxybenzophenone
611-99-4

4,4'-Dihydroxybenzophenone

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

bis(4-hydroxyphenyl)methanone O-isobutyl oxime

bis(4-hydroxyphenyl)methanone O-isobutyl oxime

Conditions
ConditionsYield
In ethanol at 20℃; Inert atmosphere;99%
2,7-bis(N'-ethoxycarbonylthiourea)-9H-fluorene
853579-43-8

2,7-bis(N'-ethoxycarbonylthiourea)-9H-fluorene

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

2,7-bis(N'-ethoxycarbonyl-N''-isobutoxy)guanidino-9H-fluorene
853579-28-9

2,7-bis(N'-ethoxycarbonyl-N''-isobutoxy)guanidino-9H-fluorene

Conditions
ConditionsYield
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In 1,4-dioxane; dichloromethane at 20℃;93%
methyl 2-(4-hydroxybenzyl)-3-oxobutanoate
157284-85-0

methyl 2-(4-hydroxybenzyl)-3-oxobutanoate

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

3-(2-methyl-propyl)oxyimino-2-(4-hydroxy-benzyl)-butyric acid methyl ester
851181-35-6

3-(2-methyl-propyl)oxyimino-2-(4-hydroxy-benzyl)-butyric acid methyl ester

Conditions
ConditionsYield
With sodium acetate In methanol90%
With triethylamine In ethanol at 45℃; for 24h;80%
methyl 3-acetyl-5-(dipropylcarbamoyl)-benzoate
924650-01-1

methyl 3-acetyl-5-(dipropylcarbamoyl)-benzoate

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C21H32N2O4
1163142-89-9

C21H32N2O4

Conditions
ConditionsYield
In ethanol at 80℃;85%
O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

benzyl chloroformate
501-53-1

benzyl chloroformate

benzyl N-(isobutyloxy)carbamate
1174758-23-6

benzyl N-(isobutyloxy)carbamate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; Inert atmosphere;84%
C31H44O7
1446092-98-3

C31H44O7

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

((2R,3S)-3-acetoxy-6-((3S,10R,13S,17S)-17-((E)-1-(isobutoxyimino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate

((2R,3S)-3-acetoxy-6-((3S,10R,13S,17S)-17-((E)-1-(isobutoxyimino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate

Conditions
ConditionsYield
With pyridine for 3h; Reflux;84%
C31H44O7
1446092-98-3

C31H44O7

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C35H53NO7

C35H53NO7

Conditions
ConditionsYield
With pyridine at 80℃; for 4h; Inert atmosphere;84%
C32H48O9

C32H48O9

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C36H57NO9

C36H57NO9

Conditions
ConditionsYield
With pyridine at 20℃;80%
4-chloro-2-pyridine carboxylic acid chloride hydrochloride

4-chloro-2-pyridine carboxylic acid chloride hydrochloride

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

4-chloro-N-isobutoxypicolinamide
953771-92-1

4-chloro-N-isobutoxypicolinamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; for 0.5h;67%
[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-acetic acid

[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-acetic acid

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

2-[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-N-isobutoxy-acetamide

2-[(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-N-isobutoxy-acetamide

Conditions
ConditionsYield
Stage #1: [(S)-2-Benzyl-4-(3-cyclopentyloxy-4-methoxy-phenyl)-piperazin-1-yl]-acetic acid With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran; dichloromethane at 0℃; for 0.0833333h;
Stage #2: O-isobutylhydroxylamine hydrochloride With triethylamine In tetrahydrofuran; dichloromethane at 0℃; for 16h;
67%
4,5-dichloro-6-methyl-2-(6-methyl-pyridin-2-yl)-pyrimidine

4,5-dichloro-6-methyl-2-(6-methyl-pyridin-2-yl)-pyrimidine

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

5-Chloro-4-O-isobutylhydroxylamino-6-methyl-2-(6-methyl-2-pyridyl)-pyrimidine
156825-31-9

5-Chloro-4-O-isobutylhydroxylamino-6-methyl-2-(6-methyl-2-pyridyl)-pyrimidine

Conditions
ConditionsYield
With triethylamine In ethanol65%
N-[6-(3-amino-4-fluorophenoxy)imidazo[1,2-b]pyridazin-2-yl]cyclopropanecarboxamide
1005781-39-4

N-[6-(3-amino-4-fluorophenoxy)imidazo[1,2-b]pyridazin-2-yl]cyclopropanecarboxamide

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

N-[6-(4-fluoro-3-{[(isobutoxyamino)carbonyl]amino}phenoxy)imidazo[1,2-b]pyridazin-2-yl]cyclopropanecarboxamide
1005783-24-3

N-[6-(4-fluoro-3-{[(isobutoxyamino)carbonyl]amino}phenoxy)imidazo[1,2-b]pyridazin-2-yl]cyclopropanecarboxamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide63%
4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-2-pyridinecarboxylic acid

4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-2-pyridinecarboxylic acid

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-N-(2-methylpropoxy)picolinamide
1242164-27-7

4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-N-(2-methylpropoxy)picolinamide

Conditions
ConditionsYield
Stage #1: 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid; O-isobutylhydroxylamine hydrochloride With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1,2-dichloro-ethane at 23℃; for 18h;
Stage #2: With acetic acid In 1,2-dichloro-ethane
61%
stigmast-4-ene-3,6-dione
23670-94-2

stigmast-4-ene-3,6-dione

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

A

C33H55NO2

C33H55NO2

B

C37H64N2O2

C37H64N2O2

Conditions
ConditionsYield
With sodium acetate In ethanol at 45℃;A 41.1%
B 51.3%
stigmast-4-ene-3,6-dione
23670-94-2

stigmast-4-ene-3,6-dione

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

A

C33H55NO2

C33H55NO2

B

C37H64N2O2

C37H64N2O2

Conditions
ConditionsYield
With sodium acetate In ethanol Heating;A 41.1%
B 51.3%
Ph(3-Cl)(5-OCF3)-(R)CH(OH)C(O)-Aze-Pab(Teoc)
433938-50-2

Ph(3-Cl)(5-OCF3)-(R)CH(OH)C(O)-Aze-Pab(Teoc)

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

Ph(3-Cl)(5-OCF3)-(R)CH(OH)C(O)-Aze-Pab(OiBu)
433938-52-4

Ph(3-Cl)(5-OCF3)-(R)CH(OH)C(O)-Aze-Pab(OiBu)

Conditions
ConditionsYield
Stage #1: Ph(3-Cl)(5-OCF3)-(R)CH(OH)C(O)-Aze-Pab(Teoc); O-isobutylhydroxylamine hydrochloride In acetonitrile at 60℃;
Stage #2: With trifluoroacetic acid In dichloromethane at 20℃; for 3h;
45%
(3-chloro-4-methanesulfonyl-phenyl)-oxo-acetic acid methyl ester
393165-03-2

(3-chloro-4-methanesulfonyl-phenyl)-oxo-acetic acid methyl ester

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

(E)-(3-chloro-4-methanesulfonyl-phenyl)-isobutoxyimino-acetic acid methyl ester
1033780-30-1

(E)-(3-chloro-4-methanesulfonyl-phenyl)-isobutoxyimino-acetic acid methyl ester

Conditions
ConditionsYield
In methanol at 70℃; for 3h;35%
mitomycin A
4055-39-4

mitomycin A

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

<1aS-(1aα,8β,8aα,8bα)>-8<<(aminocarbonyl)oxy>methyl>-6-(isobutyloxy)imino-8a-methoxy-5-methyl-1,1a,2,5,8,8a,8b-heptahydroazilidino<2',3':3,4>pyrrolo<1,2-a>indole-4,7-dione

<1aS-(1aα,8β,8aα,8bα)>-8<<(aminocarbonyl)oxy>methyl>-6-(isobutyloxy)imino-8a-methoxy-5-methyl-1,1a,2,5,8,8a,8b-heptahydroazilidino<2',3':3,4>pyrrolo<1,2-a>indole-4,7-dione

Conditions
ConditionsYield
With triethylamine In methanol for 18h; Ambient temperature;30%
O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

mitomycin A
4055-39-4

mitomycin A

8-{[(aminocarbonyl) oxy]methyl}-6-[(isobutyloxy)imino]-8a-methoxy-5-methyl1,1a,2,5,6,8,8a,8b-octahydro-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione
114429-87-7

8-{[(aminocarbonyl) oxy]methyl}-6-[(isobutyloxy)imino]-8a-methoxy-5-methyl1,1a,2,5,6,8,8a,8b-octahydro-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione

Conditions
ConditionsYield
With triethylamine In methanol29.6%
O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

N-Cyanoguanidine
127099-85-8, 780722-26-1

N-Cyanoguanidine

Isobutyloxy-diguanid
98962-02-8

Isobutyloxy-diguanid

Conditions
ConditionsYield
In ethanol
O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

ethyl 2-chloronicotinate
1452-94-4

ethyl 2-chloronicotinate

ethyl 2-(isobutoxyamino)nicotinate
686267-50-5

ethyl 2-(isobutoxyamino)nicotinate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 140℃; for 24h;
(E)-tert-butyl (4-acetamido-3,5-dichlorobenzylamino)(3-(4-methoxyphenyl)-3-oxopropanamido)methylenecarbamate
951676-43-0

(E)-tert-butyl (4-acetamido-3,5-dichlorobenzylamino)(3-(4-methoxyphenyl)-3-oxopropanamido)methylenecarbamate

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

(E)-N-((4-acetamido-3,5-dichlorobenzylamino)-(amino)methylene)-3-(isobutoxyimino)-3-(4-methoxyphenyl)propanamide

(E)-N-((4-acetamido-3,5-dichlorobenzylamino)-(amino)methylene)-3-(isobutoxyimino)-3-(4-methoxyphenyl)propanamide

Conditions
ConditionsYield
In ethanol at 80℃; for 2h;
7-fluoro-4-oxo-4H-chromene-2-carboxylic acid {1-[3-fluoro-4-(2-oxo-ethoxy)-benzyl]-piperidin-4-yl}-amide
865450-71-1

7-fluoro-4-oxo-4H-chromene-2-carboxylic acid {1-[3-fluoro-4-(2-oxo-ethoxy)-benzyl]-piperidin-4-yl}-amide

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

C28H31F2N3O5

C28H31F2N3O5

Conditions
ConditionsYield
In methanol at 20℃;
O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

4-fluorobenzaldehyde
459-57-4

4-fluorobenzaldehyde

4-fluorobenzaldehyde O-isobutyloxime

4-fluorobenzaldehyde O-isobutyloxime

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

4-methoxy-phenyl-sulphonyl chloride
98-68-0

4-methoxy-phenyl-sulphonyl chloride

N1-isobutoxy-4-methoxy-1-benzenesulfonamide

N1-isobutoxy-4-methoxy-1-benzenesulfonamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran
1-[2-methyl-8-2,4,6-trimethyl-phenyl)quinolin4-yl]-propan-1-one

1-[2-methyl-8-2,4,6-trimethyl-phenyl)quinolin4-yl]-propan-1-one

1-[2-Methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-propan-1-one (E)-O-methyl-oxime
342431-74-7

1-[2-Methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-propan-1-one (E)-O-methyl-oxime

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

1-[2-Methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-propan-1-one O-isobutyl-oxime
342431-81-6

1-[2-Methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-propan-1-one O-isobutyl-oxime

Conditions
ConditionsYield
With sodium acetate; potassium carbonate In ethanol; hexane
2',4'-dichloro-2-(pyridin-3-yl)-acetophenone
83227-42-3

2',4'-dichloro-2-(pyridin-3-yl)-acetophenone

O-isobutylhydroxylamine hydrochloride
6084-58-8

O-isobutylhydroxylamine hydrochloride

2',4'-Dichloro-2-(3-pyridyl)acetophenone O-isobutyloxime

2',4'-Dichloro-2-(3-pyridyl)acetophenone O-isobutyloxime

Conditions
ConditionsYield
With sodium carbonate In ethanol

6084-58-8Relevant academic research and scientific papers

Design, synthesis and evaluation of wound healing activity for β-sitosterols derivatives as potent Na+/K+-ATPase inhibitors

Cui, Shaoyu,Jiang, Hongli,Chen, Lei,Xu, Jian,Sun, Wenzhuo,Sun, Haopeng,Xie, Zijian,Xu, Yunhui,Yang, Fubai,Liu, Wenyuan,Feng, Feng,Qu, Wei

, (2020/01/31)

β-Sitosterols, is a common steroid that can be identified in a variety of plants and their efficacy in promoting wound healing has been demonstrated. Na+/K+-ATPase, more than a pump, its signal transduction function for involvement in cell growth regulation attracts widespread concern. The Na+/K+-ATPase/Src receptor complex can serve as a receptor involved in multiple signaling pathways including promoting wound healing pathways. To finding potent accelerating wound healing small molecular, we choose the high inhibitory activity of Na+/K+-ATPase and non-cardiotoxic natural compound, β-sitosterol as the substrate. A series of β-sitosterol derivatives were designed, synthesized and evaluated as potential Na+/K+-ATPase inhibitors. Among them, compounds 31, 47, 49, showed improved inhibitory activity on Na+/K+-ATPase, with IC50 value of 3.0 μM, 3.4 μM, 2.2 μM, which are more potent than β-sitosterol with IC50 7.6 μM. Especially, compound 49 can induce cell proliferation, migration and soluble collagen production in L929 fibroblasts. Compared to model, compound 49 can accelerate wound healing in SD rats. Further studies indicated that 49 can activate the sarcoma (Src), uptake the protein kinase B (Akt), extracellular signal-regulated kinase (ERK) proteins expression in a concentration dependent manner. Finally, binding mode of compound 49 with Na+/K+-ATPase was studied, which provides insights into the determinants of potency and selectivity. These results proved β-stitosterol derivative 49 can serve as an effective inhibitor of Na+/K+-ATPase and potential candidate for accelerating wound healing agents.

Sterol derivatives and its preparation method and application

-

Paragraph 0111-0113, (2019/05/19)

The invention discloses a sterol derivative of beta-sitosterol, beta-stigmasterol and cholesterol, and is shown as a formula VI. The invention also discloses a preparation method of the sterol derivative. The invention also discloses application of the sterol derivative to the aspect of preparation of wound healing promoting medicine. By starting from easily obtained natural products, the beta-sitosterol, the beta-stigmasterol and the cholesterol are used as starting raw materials; the synthetic method is simple; better operability and reaction yield are realized. The prepared sterol derivative has the obvious wound healing promoting activity; the multiplication, migration and collagen synthesis capability on L929 mechanocytes is obviously higher than that of the raw material and positive control medicine recombinant human bFGF (basic fibroblast growth factor). Compared with protide type medicine (such as bFGF), the prepared sterol derivative has more diversified dosage forms and medication modes; the reference is provided for the application in the field of wound healing promoting. The formula VI is shown as the accompanying diagram.

Tandem Functionalization in a Highly Branched Polymer with Layered Structure

Cao, Xiaosong,Shi, Yi,Gan, Weiping,Gao, Haifeng

supporting information, p. 5974 - 5981 (2018/03/26)

A hyperbranched polymer with multilayer structure was developed to demonstrate the possibility of highly efficient tandem functionalization reactions at different domains within one nanostructured platform. The polymer scaffold was constructed by chain-growth copper-catalyzed azide–alkyne cycloaddition polymerization of three functional monomers with sequential monomer addition in one pot. Subsequent reactions with different monomer units resulted in efficient functionalization of each segment with construction of a highly sophisticated polymer structure by a robust procedure. As a proof of concept, the ability of this polymer structure to quantitatively load six species of guest molecules through three different types of conjugation reactions was demonstrated.

Identification of novel estrogen receptor (ER) agonists that have additional and complementary anti-cancer activities via ER-independent mechanism

Kim, Taelim,Kim, Hye-In,An, Ji-Young,Lee, Jun,Lee, Na-Rae,Heo, Jinyuk,Kim, Ji-Eun,Yu, Jihyun,Lee, Yong Sup,Inn, Kyung-Soo,Kim, Nam-Jung

supporting information, p. 1844 - 1848 (2016/07/27)

In this study, a series of bis(4-hydroxy)benzophenone oxime ether derivatives such as 12c, 12e and 12h were identified as novel estrogen receptor (ER) agonists that have additional and complementary anti-proliferative activities via ER-independent mechanism in cancer cells. These compounds are expected to overcome the therapeutic limitation of existing ER agonists such as estradiol and tamoxifen, which have been known to induce the proliferation of cancer cells.

NOVEL VASCULAR LEAKAGEAGE INHIBITOR

-

Paragraph 0102, (2015/01/07)

The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

Glucal-conjugated sterols as novel vascular leakage blocker: Structure-activity relationship focusing on the C17-side chain

Kim, Kyeojin,Maharjan, Sony,Lim, Changjin,Kim, Nam-Jung,Agrawal, Vijayendra,Han, Young Taek,Lee, Sujin,An, Hongchan,Yun, Hwayoung,Choi, Hyun-Jung,Kwon, Young-Guen,Suh, Young-Ger

, p. 184 - 194 (2014/03/21)

A series of glucal-conjugated sterols as novel vascular leakage blocker were identified through design, synthesis and biologically evaluation. In addition, the structure-activity relationship (SAR) of the glucal-conjugated sterols focusing on the C17-side chain was also established. The sterol analogs linked with the rigid C17-side chain side chains exhibited potent cell survival activities. In particular, analog 21l, which possesses a cyclopentyl oxime moiety, was shown to have excellent pharmacological effects on retinal vascular leakage in a diabetic mouse model.

Synthesis and fungicidal activity of macrolactams and macrolactones with an oxime ether side chain

Huang, Jia-Xing,Jia, Yue-Mei,Liang, Xiao-Mei,Zhu, Wei-Juan,Zhang, Jian-Jun,Dong, Yan-Hong,Yuan, Hui-Zu,Qi, Shu-Hua,Wu, Jin-Ping,Chen, Fu-Heng,Wang, Dao-Quan

experimental part, p. 10857 - 10863 (2009/11/30)

Three series of novel macrolactams and macrolactones - 12-alkoxyimino- tetradecanlactam, 12-alkoxyiminopentadecanlactam, and 12-alkoxyiminodecanlactone derivatives (7A, 7B, and 7C) - were synthesized from corresponding 12-oxomacrolactams and 12-oxomacrolactone. Their structures were confirmed by 1H NMR and elemental analysis. The Z and E isomers of 7A and 7B were separated, and their configurations were determined by 1H NMR. These compounds showed fair to excellent fungicidal activities against Rhizoctonia solani Kuehn. It is interesting that the Z and E isomers of most of the compounds have quite different fungicidal activities. The fact that the compounds have a gradual increase of fungicidal activity in the order of 7A, 7C, and 7B indicated that the macrocyclic derivatives with a hydrogen-bonding acceptor (=N-O-) and a hydrogen-bonding donor (-CONH-) on the ring, and a three methylenes distance (CH2CH2CH2) between these two functional groups, exhibited the best fungicidal activity. The bioassay also showed that 7B not only has good fungicidal activity but also may have a broad spectrum of fungicidal activities.

Probing the 'active site' of diamine oxidase: Structure-activity relations for histamine potentiation by O-alkylhydroxylamines on colonic epithelium

High,Prior,Bell,Rangachari

, p. 490 - 501 (2007/10/03)

The responses of the canine colonic epithelium to histamine are potentiated by O-alkylhydroxylamines. A study of a series of such compounds suggested that active compounds had the structure R-O-NH2, substitution of a nitrogen led to total loss of activity. The locus of the potentiation effect was traced to the inhibition of diamine oxidase. A new series of aliphatic and aromatic O-alkylhydroxylamines were synthesized to explore further the structure-activity relations of this effect. The potentiating effects of these compounds were determined by examining the changes in short circuit current (I(sc)) produced by histamine and from the activity of a soluble preparation of diamine oxidase. We found that 1) branched compounds are less active than their straight chain counterparts, 2) greater steric bulk of the aliphatic substituent decreased activity, 3) the presence of a double bond had no significant effect though a triple bond reduced activity, 4) longer straight chain compounds were less active than the shorter chain derivatives and 5) all benzylic compounds were less active than the straight chain aliphatics. O-1-benzyl was inactive however the meta or para oxygen substituted compounds as well as the O-(1-E-Cinnamyl) derivative were active. A current model for the action of diamine oxidase proposes a crucial role for a trihydroxyphenylalanine quinone cofactor as part of the active site together with a copper atom. Using molecular modeling based on our inhibition data we are able to define the region of space that is just beyond the reactive carbonyl of the trihydroxyphenylalanine residue at the active site of diamine oxidase. We suggest that a negatively charged species, such as an aspartate or a glutamate, resides in a trough about 7 to 8 A from the trihydroxyphenylalanine carbonyl carbon and this species aids in the strong selective binding of substrates such as putrescine and histamine.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 6084-58-8